Obeticholic Acid for Prevention in Barrett's Esophagus
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of obeticholic acid in treating patients with
Barrett's esophagus. Bile acids present in duodenogastroesophageal reflux contribute to
neoplastic progression in Barrett's esophagus. Obeticholic acid, may help increase bile flow
from the liver while suppressing bile acid production, therefore reducing the exposure of the
liver to toxic levels of bile acids which is potentially linked to cancer development.